These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 10344904)

  • 1. The problem of protocol driven costs in pharmacoeconomic analysis.
    Coyle D; Lee KM
    Pharmacoeconomics; 1998 Oct; 14(4):357-63. PubMed ID: 10344904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Real world designs in economic evaluation. Bridging the gap between clinical research and policy-making.
    Baltussen R; Leidl R; Ament A
    Pharmacoeconomics; 1999 Nov; 16(5 Pt 1):449-58. PubMed ID: 10662392
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Collection of health-economic data alongside clinical trials: is there a future for piggyback evaluations?
    O'Sullivan AK; Thompson D; Drummond MF
    Value Health; 2005; 8(1):67-79. PubMed ID: 15841896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Protocol-driven costs in trial-based pharmacoeconomic analyses.
    Gandjour A
    Expert Rev Pharmacoecon Outcomes Res; 2011 Dec; 11(6):673-5. PubMed ID: 22098282
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Statistical analysis in pharmacoeconomic studies. A review of current issues and standards.
    Coyle D
    Pharmacoeconomics; 1996 Jun; 9(6):506-16. PubMed ID: 10160478
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized controlled trials and neurosurgery: the ideal fit or should alternative methodologies be considered?
    Mansouri A; Cooper B; Shin SM; Kondziolka D
    J Neurosurg; 2016 Feb; 124(2):558-68. PubMed ID: 26315006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacoeconomic evaluation in the real world. Effectiveness versus efficacy studies.
    Revicki DA; Frank L
    Pharmacoeconomics; 1999 May; 15(5):423-34. PubMed ID: 10537960
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Procedures and methods of benefit assessments for medicines in Germany].
    Bekkering GE; Kleijnen J
    Dtsch Med Wochenschr; 2008 Dec; 133 Suppl 7():S225-46. PubMed ID: 19034813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Procedures and methods of benefit assessments for medicines in Germany.
    Bekkering GE; Kleijnen J
    Eur J Health Econ; 2008 Nov; 9 Suppl 1():5-29. PubMed ID: 18987905
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological management of chronic lower back pain: a review of cost effectiveness.
    Haas M; De Abreu Lourenco R
    Pharmacoeconomics; 2015 Jun; 33(6):561-9. PubMed ID: 25604096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Relevance of pharmacoeconomic analyses to price and reimbursement decisions in Austria].
    Führlinger S
    Wien Med Wochenschr; 2006 Dec; 156(23-24):612-8. PubMed ID: 17211765
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Designing naturalistic prospective studies of economic and effectiveness outcomes associated with novel antipsychotic therapies.
    Tunis SL; Johnstone BM; Kinon BJ; Barber BL; Browne RA
    Value Health; 2000; 3(3):232-42. PubMed ID: 16464187
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current state and challenges of pharmacoeconomic evaluation in Korea].
    Choi SE
    J Prev Med Public Health; 2008 Mar; 41(2):74-9. PubMed ID: 18385546
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-effectiveness analysis alongside clinical trials II-An ISPOR Good Research Practices Task Force report.
    Ramsey SD; Willke RJ; Glick H; Reed SD; Augustovski F; Jonsson B; Briggs A; Sullivan SD
    Value Health; 2015 Mar; 18(2):161-72. PubMed ID: 25773551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. What do national pharmacoeconomic guidelines recommend regarding the statistical analysis of trial-based economic evaluations?
    van Dongen JM; El Alili M; Varga AN; Guevara Morel AE; Jornada Ben A; Khorrami M; van Tulder MW; Bosmans JE
    Expert Rev Pharmacoecon Outcomes Res; 2020 Feb; 20(1):27-37. PubMed ID: 31731882
    [No Abstract]   [Full Text] [Related]  

  • 17. Memantine: a pharmacoeconomic review of its use in moderate-to-severe Alzheimer's disease.
    Plosker GL; Lyseng-Williamson KA
    Pharmacoeconomics; 2005; 23(2):193-206. PubMed ID: 15748093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of randomised controlled trials for producing cost-effectiveness evidence: potential impact of design choices on sample size and study duration.
    Backhouse ME
    Pharmacoeconomics; 2002; 20(15):1061-77. PubMed ID: 12456201
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Paclitaxel: a pharmacoeconomic review of its use in non-small cell lung cancer.
    Plosker GL; Hurst M
    Pharmacoeconomics; 2001; 19(11):1111-34. PubMed ID: 11735678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical trial-based cost-effectiveness analyses of antipsychotic use.
    Polsky D; Doshi JA; Bauer MS; Glick HA
    Am J Psychiatry; 2006 Dec; 163(12):2047-56. PubMed ID: 17151153
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.